Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03412799 · ClinicalTrials.gov registry record · Phase 1
Study of SBP-101 Combined With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
A Phase 1 study, sponsored by Panbela Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
NCT03412799 is a Phase 1 study that has completed, run by Panbela Therapeutics. The registered enrollment target is 50 participants.
The verdict
NCT03412799, a Phase 1 study, has completed, sponsored by Panbela Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
This is an open-label phase 1A/1B study to assess the safety, tolerability and pharmacokinetics of SBP-101 when combined with nab-paclitaxel and gemcitabine in subjects with previously untreated metastatic pancreatic ductal adenocarcinoma and to identify a recommended phase 2 dose. The study will also assess preliminary efficacy of the 3-drug treatment combination.
Interventions
- DRUG nab-paclitaxel
- DRUG SBP-101
- DRUG Gemcitabine Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2018-06-04 |
| Est. Completion | 2022-02-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03412799
The ClinicalTrials.gov registry entry for NCT03412799 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Panbela Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which nab-paclitaxel is the first listed.
NCT03412799 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03412799 about?
NCT03412799 is a clinical study titled "Study of SBP-101 Combined With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer". This is an open-label phase 1A/1B study to assess the safety, tolerability and pharmacokinetics of SBP-101 when combined with nab-paclitaxel and gemcitabine in subjects with previously untreated metastatic pancreatic ductal adenocarcinoma and to identify a recommended phase 2 dose. The study will al...
What is the current status of trial NCT03412799?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2018-06-04. Estimated completion is 2022-02-28.
What interventions are being tested in trial NCT03412799?
The interventions under investigation include: nab-paclitaxel (DRUG), SBP-101 (DRUG), Gemcitabine Injection (DRUG).
Who is sponsoring clinical trial NCT03412799?
This trial is sponsored by Panbela Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.